{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:25:26Z","timestamp":1793395526614,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL007605"],"award-info":[{"award-number":["5T32HL007605"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00408-019-00306-4","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T06:02:45Z","timestamp":1578376965000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-0278","authenticated-orcid":false,"given":"Lucas M.","family":"Kimmig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-6015","authenticated-orcid":false,"given":"Remzi","family":"Bag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"issue":"1","key":"306_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M et al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67\u2013119","journal-title":"Eur Heart J"},{"issue":"2","key":"306_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1378\/chest.14-0793","volume":"146","author":"DB Taichman","year":"2014","unstructured":"Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB et al (2014) Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 146(2):449\u2013475","journal-title":"Chest"},{"key":"306_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/TCRM.S75122","volume":"11","author":"BL LeVarge","year":"2015","unstructured":"LeVarge BL (2015) Prostanoid therapies in the management of pulmonary arterial hypertension. Ther Clin Risk Manag 11:535\u2013547","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"306_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herv\u00e9 P, Rainisio M, Simonneau G (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol 40(4):780\u2013788","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"306_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1086\/529552","volume":"29","author":"AJ Kallen","year":"2008","unstructured":"Kallen AJ, Lederman E, Balaji A, Trevino I, Petersen EE, Shoulson R, Saiman L, Horn EM, Gomberg-Maitland M, Barst RJ et al (2008) Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 29(4):342\u2013349","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"306_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11630780-000000000-00000","volume":"10","author":"A Roman","year":"2012","unstructured":"Roman A, Barbera JA, Escribano P, Sala ML, Febrer L, Oyaguez I, Sabater E, Casado MA (2012) Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Appl Health Econ Health Policy 10(3):175\u2013188","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"306_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.hrtlng.2011.05.007","volume":"41","author":"H Hall","year":"2012","unstructured":"Hall H, Cote J, McBean A, Purden M (2012) The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart Lung 41(1):35\u201343","journal-title":"Heart Lung"},{"key":"306_CR8","doi-asserted-by":"publisher","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","volume":"53","author":"N Gali\u00e8","year":"2019","unstructured":"Gali\u00e8 N, Channick RN, Frantz RP et al (2019) Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 53:1801889","journal-title":"Eur Respir J"},{"key":"306_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pupt.2016.07.007","volume":"40","author":"A Ataya","year":"2016","unstructured":"Ataya A, Somoracki A, Cope J, Alnuaimat H (2016) Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension. Pulm Pharmacol Ther 40:39\u201343","journal-title":"Pulm Pharmacol Ther"},{"issue":"10","key":"306_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.amjcard.2012.07.012","volume":"110","author":"VA de Jesus Perez","year":"2012","unstructured":"de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E et al (2012) Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 110(10):1546\u20131550","journal-title":"Am J Cardiol"},{"issue":"5","key":"306_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/jcpt.12170","volume":"39","author":"CY Enderby","year":"2014","unstructured":"Enderby CY, Soukup M, Al Omari M, Zeiger T, Burger C (2014) Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series. J Clin Pharm Ther 39(5):496\u2013500","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"306_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/2045-8932.109926","volume":"3","author":"A Raina","year":"2013","unstructured":"Raina A, Coons JC, Kanwar M, Murali S, Sokos G, Benza RL (2013) Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension. Pulm Circ 3(1):116\u2013120","journal-title":"Pulm Circ"},{"issue":"4","key":"306_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1086\/688711","volume":"6","author":"R Oudiz","year":"2016","unstructured":"Oudiz R, Agarwal M, Rischard F, De Marco T (2016) An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension. Pulm Circ 6(4):532\u2013538","journal-title":"Pulm Circ"},{"issue":"2","key":"306_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.healun.2016.06.019","volume":"36","author":"MM Chakinala","year":"2017","unstructured":"Chakinala MM, Feldman JP, Rischard F, Mathier M, Broderick M, Leedom N, Laliberte K, White RJ (2017) Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant 36(2):193\u2013201","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"306_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/FJC.0000000000000357","volume":"67","author":"KS Parikh","year":"2016","unstructured":"Parikh KS, Rajagopal S, Fortin T, Tapson VF, Poms AD (2016) Safety and tolerability of high-dose inhaled treprostinil in pulmonary hypertension. J Cardiovasc Pharmacol 67(4):322\u2013325","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00306-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-019-00306-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00306-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:36:56Z","timestamp":1609893416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-019-00306-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s00408-019-00306-4","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"12 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Lucas Kimmig has no relevant conflicts of interest to disclose. Lucas Kimmig received support from the NIH T32 Training Grant in Respiratory Biology (5T32HL007605). Chuanhong Liao has no relevant conflict of interest to disclose. Remzi Bag has served as consultant\/speaker for Actelion Pharmaceuticals, Cipla, Gilead Sciences, and Bayer; and has received research grants from Gilead Sciences, Reata Pharma, Actelion, Medtronics, Liquidia Technologies, PhaseBio, Arena Pharma, Lung Biotechnology and United Therapeutics Corp. This work was supported by a grant from United Therapeutics Corporation. The funding source was not involved in the data collection, analysis, or interpretation, and did not have the right to approve or disapprove publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}